Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Status:
Recruiting
Trial end date:
2025-02-27
Target enrollment:
Participant gender:
Summary
This phase Ib trial determines if samples from a patient's cancer can be tested to find
combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
This study is also being done to understand why cancer drugs can stop working and how
different cancers in different people respond to different types of therapy.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Oregon Health and Science University Prospect Creek Foundation